Log in with your email address username.

×

[Editorial] CAR T-cells: an exciting frontier in cancer therapy

On Aug 30, the US Food and Drug Administration (FDA) approved tisagenlecleucel (marketed by Novartis as Kymriah) as the first ever treatment that genetically modifies patients’ own T cells. The approval is for children and young adults (up to 25 years of age) with relapsed or refractory acute B-cell lymphoblastic leukaemia—a leading cause of childhood cancer deaths. This treatment option is currently limited to 20 specially certified centres in the USA because of the complexity of the procedure and potentially serious side-effects.

email